On Friday, Roivant Sciences Ltd (NASDAQ: ROIV) was -0.73% drop from the session before settling in for the closing price of $23.3. A 52-week range for ROIV has been $8.73 – $23.91.
Annual sales at Healthcare sector company slipped by -99.51% over the past five years. When this article was written, the company’s average yearly earnings per share was at -365.48%. With a float of $437.45 million, this company’s outstanding shares have now reached $689.70 million.
Roivant Sciences Ltd (ROIV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Roivant Sciences Ltd stocks. The insider ownership of Roivant Sciences Ltd is 37.10%, while institutional ownership is 64.51%. The most recent insider transaction that took place on Jan 12 ’26, was worth 4,384,000. In this transaction President & Immunovant CEO of this company sold 200,000 shares at a rate of $21.92, taking the stock ownership to the 1,654,597 shares. Before that another transaction happened on Jan 12 ’26, when Company’s Officer proposed sale 200,000 for $21.92, making the entire transaction worth $4,383,694.
Roivant Sciences Ltd (ROIV) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.2 earnings per share (EPS) during the time that was better than consensus figure (set at -0.24) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -365.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -25.94% during the next five years compared to -99.51% drop over the previous five years of trading.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
You can see what Roivant Sciences Ltd (ROIV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 33.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 791.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.26 in one year’s time.
